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Background: Ongoing research is focusing on the identification of those individuals
with mild cognitive impairment (MCI) who are most likely to convert to Alzheimer’s
disease (AD). We investigated whether recognition memory tasks in combination with
delayed recall measure of episodic memory and CSF biomarkers can predict MCI to AD
conversion at 24-month follow-up.
Methods: A total of 397 amnestic-MCI subjects from Alzheimer’s disease Neuroimaging
Initiative were included. Logistic regression modeling was done to assess the predictive
value of all RAVLT measures, risk factors such as age, sex, education, APOE genotype,
and CSF biomarkers for progression to AD. Estimating adjusted odds ratios was used
to determine which variables would produce an optimal predictive model, and whether
adding tests of interaction between the RAVLT Delayed Recall and recognition measures
(traditional score and d-prime) would improve prediction of the conversion from a-MCI
to AD.
Results: 112 (28.2%) subjects developed dementia and 285 (71.8%) subjects did
not. Of the all included variables, CSF Aβ1-42 levels, RAVLT Delayed Recall, and the
combination of RAVLT Delayed Recall and d-prime were predictive of progression to AD
(χ2 = 38.23, df = 14, p < 0.001).
Conclusions: The combination of RAVLT Delayed Recall and d-prime measures may
be predictor of conversion from MCI to AD in the ADNI cohort, especially in combination
with amyloid biomarkers. A predictive model to help identify individuals at-risk for
dementia should include not only traditional episodic memory measures (delayed recall
or recognition), but also additional variables (d-prime) that allow the homogenization of
the assessment procedures in the diagnosis of MCI.
Keywords: disease progression, memory, recognition discriminability, mild cognitive impairment, Alzheimer’s
disease, signal detection theory
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INTRODUCTION
Mild Cognitive Impairment (MCI) is a common condition
defined as transitional state between normal cognition and
dementia (Petersen et al., 2001). In general, subjects with MCI
convert to dementia at an annual rate in the range of 10–15%
(Farias et al., 2009). Predicting who among a group of MCI
patients are more likely to further decline in cognition would
be essential to ensure an early intervention and appropriate
treatment as well as future preventive and treatment trials.
Of the MCI subtypes, patients with amnestic MCI (a-MCI)
are at greatest risk. Poor delayed recall and recognition memory
is a well-established pattern in the Alzheimer’s disease (AD)
literature, which is considered to reflect deficits in storage caused
by deficient consolidation of new memory traces (Weintraub
et al., 2012). Abundant evidence indicates delayed recall scores
in word-list learning tasks such as the Rey Auditory Verbal
Learning Test (RAVLT) (Rey, 1941, 1964) are perhaps the
most challenging and accurate measures of episodic memory
when used to accurately predict diagnostic conversion to AD
(Estévez-González et al., 2003; Maruff et al., 2004; Griffith et al.,
2006). It should be noted that other memory tests have shown
predictive validity for clinical progression from MCI to AD,
including Free and Cued Selective Reminding Test (FCSRT-FR)
(Derby et al., 2013), delayed recall of story memory and verbal
paired associates (Guarch et al., 2008) and visuospatial paired
associate learning (Ahmed et al., 2008). Some authors (Dubois
and Albert, 2004; Dubois et al., 2007) proposed using memory
tests that provide encoding and retrieval facilities, such as the
free and cued recall test (Grober and Buschke, 1987; Gainotti
et al., 2014) to improve the prediction of MCI-AD conversion.
However, a recently review showed inconclusive results (Grober
and Buschke, 1987; Carlesimo et al., 2011; Gainotti et al., 2014).
It is mandatory to have adequate and well-controlled studies
to determine whether that test paradigms can improve the
prediction of conversion fromMCI to AD.
Thus, most clinical studies assume that memory is a single
entity and extrapolate the results of a single memory measure
(e.g., delayed recall or recognition task, verbal, or visual memory
test) to the global memory functioning. Episodic memory can be
subdivided according to the different stages on the reproduction
process (e.g., free recall, cued recall, or recognition) and this
multicomponent analysis may be used to describe the real risk of
MCI to AD conversion. To our knowledge, it is not clear whether
measurement of recognition task adds benefit for measuring
conversion over time in a clinical cohort.
In the present study, we investigated whether recognition
memory tasks in combination with delayed recall measure of
episodic memory and CSF biomarkers can predict MCI to
AD conversion at 24-month follow-up. We chose to examine
this issue using ADNI, a public data set with a large sample
and prospective nature. Delayed recall is the most important
predictor for MCI to AD conversion. In addition, AD’s patient
deficits are evident in recognition tasks, with the presence of
many false alarms errors. Most studies simplify recognition task
by only registering the number of correct identifications (hits),
without the inclusion of false alarms in their interpretation. Based
on the signal detection theory, a discriminability recognition
index (d-prime) can be calculated including both hits and false
alarms (Russo et al., 2016). In addition, d-prime has been
shown to distinguish healthy older adults from those with a-
MCI or mild AD. We hypothesized that the addition of the
d-prime measure to the delayed recall task would be good
predictor of conversion from a-MCI to AD at 24-month follow-
up in combination with CSF biomarkers related to AD, which
were significant discriminators in other studies (Tabert et al.,
2006; Lanari and Parnetti, 2009; Gomar et al., 2011) and were
independently associated with future cognitive decline compared
to other surrogate of neurodegeneration as MRI (Vemuri et al.,
2009). We also thought that the addition of the traditional
recognition score would be not a good predictor in combination
with the same markers.
With the concepts explained in these paragraphs, we
measured:
(i) The main effect of the cognitive measures: RAVLT delayed
recall, traditional RAVLT recognition, and d-prime.
(ii) The main effect of the known risk factors such as age, sex,
education, and APOE genotype.
(iii) The main effect of the CSF biomarkers related to AD:
Aβ1-42, P-tau181, and total tau.
(iv) The interaction between RAVLT delayed recall and
recognition measures (traditional score and d-prime),
which represents the influence of the delayed recall on the
magnitude of the recognition task.
Many papers have looked at specific clinical markers and
biomarkers in isolation but never set up a study to compare
the added effect to predict conversion to dementia. We believed
that this analysis would help to interpret the MCI-AD transition
in this sample and to propose the d-prime as an early useful
cognitive marker to predict AD conversion.
MATERIALS AND METHODS
Subjects
Data used in the preparation of this article were obtained
from the Alzheimer’s disease Neuroimaging Initiative (ADNI)
database (adni.loni.usc.edu). The ADNI was launched in 2003 by
the National Institute on Aging (NIA), the National Institute of
Biomedical Imaging and Bioengineering (NIBIB), the Food and
Drug Administration (FDA), private pharmaceutical companies
and non-profit organizations, as a $60 million, 5-year public-
private partnership. The primary goal of ADNI has been to
test whether serial magnetic resonance imaging (MRI), positron
emission tomography (PET), other biological markers, and
clinical and neuropsychological assessment can be combined to
measure the progression of mild cognitive impairment (MCI)
and early Alzheimer’s disease (AD). Determination of sensitive
and specific markers of very early AD progression is intended
to aid researchers and clinicians to develop new treatments and
monitor their effectiveness, as well as lessen the time and cost of
clinical trials.
The Principal Investigator of this initiative is Michael
W. Weiner, MD, VA Medical Center, and University of
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California—San Francisco. ADNI is the result of efforts of many
co-investigators from a broad range of academic institutions and
private corporations, and subjects have been recruited from over
50 sites across the U.S. and Canada. The initial goal of ADNI was
to recruit 800 subjects but ADNI has been followed by ADNI-GO
and ADNI-2. To date these three protocols have recruited over
1,500 adults, ages 55–90, to participate in the research, consisting
of cognitively normal older individuals, people with early or late
MCI, and people with early AD. The follow up duration of each
group is specified in the protocols for ADNI-1, ADNI-2, and
ADNI-GO. Subjects originally recruited for ADNI-1 and ADNI-
GO had the option to be followed in ADNI-2. For up-to-date
information, see http://www.adni-info.org (Mueller et al., 2005;
Petersen et al., 2010).
A total of 397 subjects with a-MCI from the ADNI study
were included in the current analysis. MCI subjects fulfilled
criteria for a-MCI (Petersen, 2004): nondemented subjects with
memory complaint (global CDR score = 0.5, with a Memory
Box score ≥ 0.5), MMSE score of 24–30, a Modified Hachinski
Ischemic Score (Rosen et al., 1980) ≤4, a Geriatric Depression
Score short form (Sheikh and Yesavage, 1986)<6, and preserved
instrumental activities of daily living. Subjects performed at an
objective cut-off of 1.5 standard deviations (SD) below education-
adjusted cut-off scores on the LogicalMemory IIa of theWeschler
Memory Scale-Revised (Wechsler, 1987). The summary of the
baseline characteristics of the ADNI subjects indicated that the
subjects with MCI presented memory-only deficits (Petersen
et al., 2010).
The subjects with a-MCI were divided into two groups for the
comparison between those who convert to AD dementia during
24-month follow-up and those who did not.
Psychometric Testing
The baseline characteristics of the subjects from ADNI cohort
relevant to describe their neuropsychological profile were the
Mini Mental State Examination (MMSE) (Folstein et al., 1975);
Logical memory test of immediate and delayed recognition,
Wechsler Memory Scale III (Wechsler, 1987); Boston Naming
Test (Kaplan et al., 1983); Categorical and Phonological Verbal
Fluency test (Morris et al., 1989); Digit Span Forward and
Backward (Wechsler, 1997); Trail Making Test A and B (Reitan,
1958); GDS short form (Sheikh and Yesavage, 1986); and RAVLT
(Rey, 1941, 1964).
The RAVLT consists of five learning trials in which a list of 15
words is read and the subject is asked to immediately recall orally
as many items as possible. After an interference list of 15 novel
words is read and recalled, subjects are then asked to recall words
from the initial list (5-min delayed recall). A 30-min delayed
recall trial and recognition test follow. For the recognition test,
subjects are presented with a list of the 15 studied words and
15 non-studied foils and are asked to circle all words previously
learned.
Discriminability refers to the ability to distinguish target
words from distractor words, and is widely considered the
best measure of recognition memory accuracy. Discriminability
index (d-prime = Z hits rate – Z false alarms rate)
is adapted from signal detection theory (Snodgrass and
Corwin, 1988) and is analogous to a contrast z score,
reflecting the absolute difference in standard deviation units
between subject hit rate and false alarm rate (Donaldson,
1992).
CSF Analysis
CSF was available from 198 (49.80%) patients. Methods
for cerebrospinal fluid (CSF) acquisition and biomarker
measurement using the ADNI cohort has been reported
previously (Shaw et al., 2009). In brief, CSF was collected
and stored at −80◦C at the University of Pennsylvania ADNI
Biomarker Core Laboratory. Amyloid-β from peptides 1-42
(Aβ1-42), tau phosphorylated at threonine 181 (P-tau181), and
total tau was measured using the multiplex xMAP Luminex
platform (Luminex Corp, Austin TX) with Innogenetics
(INNOBIA AlzBio3, Ghent, Belgium) immunoassay kit–based
reagents.
APOE ε4 Status
APOE ε4 status was considered as a binary variable (i.e., at least
one ε4 allele vs. none).
Statistical Analyses
Statistical analysis was performed with SPSS∗ Version 19.0
software for Windows. Independent sample t-tests were used
to assess differences in clinical, cognitive and biomarkers CSF
variables. The χ2-test was used for the analysis of gender
and APOEε4 carrier status differences between groups. The
Pearson’s test of correlation was used to measure the degree
of relationship between conversion status at 24-month follow-
up and the predictive factors. Logistic regression modeling was
done to assess the predictive value of all RAVLT measures
(Delayed Recall, Recognition, and d-prime), risk factors such as
age (in years), sex (male/female), education (in years), APOEε4
carrier status (at least 1 allele vs. none allele, MMSE score,
and CSF biomarkers levels for progression to AD. Estimating
adjusted odds ratios was used to determine which variables would
produce an optimal predictive model, and whether adding tests
of interaction between the RAVLT Delayed Recall and RAVLT
recognition measures (traditional score and d-prime) would
improve prediction of the conversion from a-MCI to AD by
including the main effects and two interaction terms (RAVLT
Delayed Recall∗RAVLT Recognition; RAVLT Delayed Recall∗d-
prime).
RESULTS
The clinical and demographic characteristics of the subjects
as well as CSF biomarkers are listed by conversion status
in Table 1. At the 24-month follow-up, 112 (28.2%) subjects
developed AD dementia (converters) and 285 (71.8%) subjects
did not (nonconverters). Those who developed AD dementia had
worse performance on baseline MMSE (t = 3.35, p = 0.001),
Delayed Recall Logical Memory (t = 5.17, p < 0.001), RAVLT
Delayed Recall (t = 5.28, p < 0.001), RAVLT Recognition
(t = 3.98, p < 0.001), and d-prime (t = 3.53, p = 0.001),
but were not significantly different with respect to sex, age,
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TABLE 1 | Demographic characteristics, cognitive tests scores, and CSF biomarker profile on the MCI sample at baseline, split according to progression
status at 24-month follow-up.
Variable a-MCI Non-converters (n = 285) a-MCI converters (n = 112) Statistical Test
t/χ2
p-value
Age, y 74.12 ± 7.1 74.3 ± 6.8 −0.96 0.339
Female, n (%) 97 (34) 44 (39) 0.97 0.352
Education, y 15.7 ± 3.1 15.5 ± 2.9 0.50 0.614
GDS 1.6 ± 1.4 1.4 ± 1.1 1.21 0.226
MMSE 27.2 ± 1.8 26.6 ± 1.6 3.35 0.001
WMS—Immediate Recall 7.5 ± 3.1 6.2 ± 3.1 3.56 0.000
WMS—Delayed Recall 4.2 ± 2.7 2.7 ± 2.2 5.52 0.000
Boston Naming Test 25.7 ± 4.0 24.9 ± 4.2 1.72 0.087
Forward Digit Span 8.2 ± 2.0 8.2 ± 2.0 −0.05 0.961
Backward Digit Span 6.3 ± 2.1 5.9 ± 1.8 1.41 0.159
Category VFT 16.1 ± 5.1 15.1 ± 4.4 1.86 0.064
TMT—A (seconds) 42.9 ± 20.9 49.9 ± 26.3 −2.83 0.395
TMT—B (seconds) 122.6 ± 69.9 152.0 ± 77.7 −3.63 0.000
RAVLT trial 1–5 32.3 ± 9.5 26.7 ± 6.1 5.76 0.000
RAVLT Delayed Recall 3.4 ± 3.5 1.5 ± 2.0 5.28 0.000
RAVLT Delayed-Intrusions 1.4 ± 1.57 1.5 ± 1.9 −0.36 0.721
RAVLT Recognition 10.1 ± 3.4 8.5 ± 3.8 3.98 0.000
RAVLT Recognition-False Alarms 1.9 ± 2.1 2.1 ± 2.6 −0.69 0.487
d-prime 1.7 ± 1.0 1.3 ± 0.9 3.42 0.001
APOEε4 carriers, n (%) 11.81 0.003
Noncarriers 147 (51.6) 38 (33.9)
Carriers 1 allele 111 (38.9) 54 (48.2)
Carriers 2 alleles 27 (9.5) 20 (17.9)
CSF biomarkers, pg/ml, n 140 58
Tau 102.3 ± 66.5 106.6 ± 45.5 −0.45 0.653
A-β1-42 172.7 ± 58.9 141.8 ± 35.2 3.72 0.000
p-Tau 181P 34.2 ± 18.8 38.6 ± 15.7 −1.57 0.117
Tau/ A-β 1-42 0.7 ± 0.7 0.8 ± 0.3 −0.67 0.506
p-Tau 181P/A-β 1-42 0.2 ± 0.2 0.3 ± 0.1 −1.62 0.106
CSF AD profile 0.5 ± 0.2 0.4 ± 0.1 3.78 0.000
Values are numbers (percentages) or mean ± SD. a-MCI, amnestic mild cognitive impairment; MMSE, Mini-Mental State Examination Test; WMS III, Wechsler Memory Scale III, Logical
memory test of immediate and delayed recall; TMT, Trail Making Test A and B; RAVLT, Rey Auditory Verbal Learning Test; CSF, cerebrospinal fluid; AD, Alzheimer’s disease.
education, and other neuropsychological tests. The proportion
of the individuals with APOEε4 was also significantly higher
in those who developed AD dementia than those who did not
(χ2 = 11.81, p = 0.003). CSF Aβ 11-42, tau, and P-tau181 levels
were available in 198 subjects from two groups (58 vs. 140)
for those who developed AD dementia and those who did not
respectively. The group of a-MCI patients who progressed to AD
dementia had lower levels of CSF Aβ42 (t = 3.71, p< 0.001) and
CSF AD profile (t = 3.78, p < 0.001) than the group of non-
progressive a-MCI patients.
Results of logistic regression analyses are shown in Table 2.
Of the variables entered into the first step, only RAVLT Delayed
Recall and CSF Aβ42 levels reached significance with the
odds of 0.79 (95% CI 0.66–0.94) and 0.99 (95% CI 0.98–
0.99), respectively. The overall model was statistically significant
(χ2 = 32.03, df = 12, p = 0.001). When both interactions
(RAVLT Delayed Recall∗RAVLT Recognition; RAVLT Delayed
Recall∗d-prime) were entered to evaluate the impact of both
recognition measures in predicting conversion, only CSF Aβ42
levels and RAVLT Delayed Recall∗d-prime interaction remained
significant in the model with the odds of 0.98 (95% CI 0.97–0.99)
and 0.75 (95% CI 0.58–0.97), respectively. Also, the overall model
was statistically significant (χ2 = 38.23, df = 14, p < 0.001).
The area under the curve was.75, and the percentage of cases
classified correctly was 77.4% at c = 0.50. Sensitivity was
0.41 and specificity was 0.93 at c = 0.50. The decrease in
deviance was the largest for the second step including CSF
Aβ42 levels and RAVLT Delayed Recall∗d-prime interaction,
indicating that adding d-prime to delayed recall increased the
predictive accuracy compared to delayed recall alone (205.354
– 199.149 = 6.205). The drop in deviance was significant
(t =−52.79, df = 196, p < 0.001). CSF markers by each
potential effect modifier (age, gender, MMSE, RAVLT delayed
recall, RAVLT recognition memory, d-prime, or APOE ε4)
Frontiers in Aging Neuroscience | www.frontiersin.org 4 March 2017 | Volume 9 | Article 46
Russo et al. Recognition Memory Predicts Alzheirmer’s Disease
TABLE 2 | Results of logistic regression analysis.
Variable Beta SE Wald Df p-value OR (95% CI)
Age 0.022 0.025 0.777 1 0.38 1.02 (0.97–1.07)
Gender (Male) 0.013 0.389 0.001 1 0.97 1.01 (0.47–2.17)
Education −0.113 0.059 3.631 1 0.06 0.89 (0.79–1.00)
MMSE −0.150 0.101 2.212 1 0.14 0.86 (0.71–1.05)
RAVLT Delayed Recall −0.239 0.092 6.764 1 0.01 0.79 (0.66–0.94)
RAVLT Recognition −0.093 0.281 0.110 1 0.74 0.91 (0.52–1.58)
d-prime 0.379 0.705 0.288 1 0.59 1.46 (0.37–5.82)
APOEε4 −0.066 0.378 0.030 1 0.86 0.94 (0.45–1.96)
Tau −0.009 0.005 3.524 1 0.06 0.99 (0.98–1.00)
Aβ1−42 −0.014 0.005 9.302 1 0.00 0.99 (0.98–0.99)
P-tau181 0.012 0.016 0.636 1 0.42 1.01 (0.98–1.04)
RAVLT Delayed Recall*RAVLT Recognition 0.036 0.035 1.058 1 0.30 1.04 (0.97–1.11)
RAVLT Delayed Recall*d-prime −0.283 0.132 4.596 1 0.03 0.75 (0.58–0.98)
MMSE, Mini-Mental State Examination Test; RAVLT, Rey Auditory Verbal Learning Test; APOE, Apolipoprotein E; Aβ1-42, Amyloid-β from peptides 1-42; P-tau181, tau phosphorylated
at threonine 181; Standard error; DF, Degrees of freedom; OR, Odds ratio; CI, Confidence interval.
interaction term was added to model; there was no change in the
results.
There were weak positive correlations between conversion
ratio to AD dementia and MMSE, RAVLT Delayed Recall,
RAVLT Recognition, and d-prime (r = 0.207, 0.299, −0.215,
0.254, respectively, n = 397, p < 0.05) (Table 3). There was also
a significant but negative correlation between conversion ratio
to AD dementia and CSF Aβ42 levels (r = −0.659, n = 198,
p < 0.001). There were also a significant but positive correlation
between conversion ratio to AD dementia and APOEε4 carrier
status, (r = 0.355, n = 397, p < 0.001), and CSF P-tau181 levels
(r = 0.429, n= 198, p< 0.001).
DISCUSSION
In this study, we demonstrated that baseline CSF Aβ1-42 levels,
RAVLT Delayed Recall, and the combination of RAVLT Delayed
Recall and Recognition Discriminability Index (d-prime) were
the strongest predictors of conversion from a-MCI to AD at 24-
month follow-up in patients in the ADNI sample. These results
were independent of other factors known to increase the risk of
developing dementia, such as age, gender, education level, and
APOEε4 status (Tabert et al., 2006; Lanari and Parnetti, 2009;
Gomar et al., 2011). We also showed that the combination of
RAVLT Delayed Recall and traditional recognition measure may
not predict MCI-AD conversion.
One might argue that the use of verbal episodic memory
markers in this context is redundant. However, this may not
be correct because the RAVLT memory measures examined as
a predictor in this paper was not part of the study inclusion
criteria in ADNI cohort (WMS-R logical memory was used).
Nevertheless, evaluation of different components of verbal
episodic memory deficit as a predictor in patients with a-MCI
may be an advantage to interpret our patients in clinical practice
or to improve their recruitment in clinical trials. Other important
issue is that the diagnostic conversions over the 24-month period
TABLE 3 | Correlations between conversion status at 24-month follow-up
and the predictive factors.
Conversion MMSE RAVLT RAVLT d-prime
ratio Delayed Recall Recognition
Conversion ratio 1.000 0.207* 0.299* 0.215* 0.254*
MMSE 0.207* 1.000 0.515* 0.457* 0.517*
RAVLT Delayed
Recall
0.299* 0.515* 1.000 0.622* 0.715*
RAVLT Recognition 0.215* 0.457* 0.622* 1.000 0.876*
d-prime 0.254* 0.517* 0.715* 0.876* 1.000
Values are Pearson’s Correlation Coefficient (r). MMSE, Mini-Mental State Examination
Test; RAVLT, Rey Auditory Verbal Learning Test.
*p < 0.05.
should be viewed with some caution. A 24-month change period
is not a sufficient amount of time to draw conclusions regarding
the likelihood of clinical change. However, we preferred not
include the 36- or 48-month period due to partially missing
baseline data.
Numerous studies that characterized the episodic memory
deficit in AD have used word list learning tasks such as those
from the Consortium to Establish a Registry for Alzheimer
Disease (CERAD) (Welsh et al., 1992), the RAVLT (Rey,
1941, 1964), and the California Verbal Learning Test (CVLT)
(Delis et al., 1991). These studies consistently showed that
AD patients are equally impaired (relative to age-matched
controls) on recognition and free recall components of
the tasks. This pattern of performance is consistent with
impaired consolidation rather than ineffective retrieval of new
information (Delis et al., 1991). This memory profile is a
useful measure for a clinical diagnosis and classification MCI
subjects.
However, MCI in general and a-MCI in particular are
heterogeneous clinical constructs, and the reported literature
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that investigated the role of different verbal episodic memory
task as a predictor of cognitive decline in MCI is variable,
with inhomogeneous results. Explicit measures of delayed recall
have been reported the best predictors of the development
of AD in MCI subjects (Gainotti et al., 2014). With respect
to the recognition memory task, we found few studies that
assessed their predictive value. Rabin et al. (2009) revealed
that logical memory recognition best predicted the progression
to AD followed closely by the delayed recall condition of
CVLT-II. Yang et al. (2012) subdivided a-MCI sample from
ADNI cohort into two subtypes, encoding failure (a-MCI-E) vs.
retrieval deficit (a-MCI-R) but did not find that a-MCI-E was
an independent prognostic factor to predict the progression to
AD. In addition to the neuropsychological predictors, current
criteria and recommendations (Dubois et al., 2007; Albert et al.,
2011) proposed that incorporation of distinctive and reliable
biomarkers of underlying AD to predict MCI-AD conversion.
Most prior studies of CSF biomarkers have showed only modest
prognostic accuracy for prediction of conversion from MCI
to AD (Vemuri et al., 2009). On the other hand, most of
these studies aimed to identify the predictive value of a set
of commonly measured variables, with classification accuracies
reaching up to 80%. However, none of these prior studies
have investigated the predictive value when combining different
related variables to homogenize the group of subjects with higher
risk of conversion.
We have found that delayed recall can make important
influence to recognition task in patients who convert to dementia,
when the hits and false alarms are considered. Considering that
memory is not a unitary concept, the strategy of combining
recall and recognition memory measures might provide a more
accurate assessment of MCI individuals who perform poorly on
list learning tasks or allow to develop an empirical perspective
of subtyping within a-MCI that may identify more homogenous
subgroups reflecting common etiology and better predictors of
decline. We considered that the simultaneous analysis of CSF
biomarkers or the combination of different assessment yielded a
better prediction of conversion fromMCI to AD.
Future research should more closely examine which memory
processes are tapped by specific tasks and the nature and extent
of decline in these processes during the insidious transition
from healthy aging to MCI to AD. This suggested subdivision
within a-MCI based on recall and recognition performance need
to be assessed using traditional delayed recall and recognition
measures, but with inclusion of additional variables (e.g.
d-prime). We also expect that future prediction studies consider
the co-occurrence effects of different variables (interactions), and
not only traditional additive (main effects) models.
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